This breakthrough strategy opens a door of hope to what could become the world's first general dengue vaccine applicant that can give full security from all serotypes of the dreadful virus. This study completed in collaboration with Singapore's Novartis Institute of Tropical Diseases and Beijing Institute of Microbiology and Epidemiology is published in the PlosPathogens journal, and can be supported by Singapore End Dengue Translational and Clinical Analysis Programme grant. However, over the years of vaccine development, scientists have learnt that the road to finding a virus of appropriate strength is fraught with problems. This hurdle is usually compounded by the complexity of the dengue virus.The scholarly research was completed at the Karolinska Institute, Sweden between 1980 and 2001.128 sufferers had to be admitted for a suicide attempt during the scholarly study period. The findings show that the chance for suicide was elevated several years before treatment and remained elevated in the a few months after treatment. In this way the drug cannot be implicated write experts wholly. Surprisingly, taking the drug was associated with a lower threat of another suicide attempt in individuals with a prior attempt. Related StoriesComputerised cognitive behavioural therapy likely to be ineffective in depressive disorder treatmentResearchers recognize potential brain-based biomarker for depressive symptomsResilience-based programs might help LGBT youths cope with negative stressorsA close view on patients upon this treatment is vital they create and the watch must be continued up to at least one 1 year after treatment is stopped.